Conference Program Home
  My Program

All Times EDT

Abstract Details

Activity Number: 378 - LiDS Student Paper Award Winners: Topic-Contributed Papers
Type: Topic Contributed
Date/Time: Wednesday, August 10, 2022 : 8:30 AM to 10:20 AM
Sponsor: Lifetime Data Science Section
Abstract #322349
Title: A Meta-Learner Framework to Estimate Individualized Treatment Effects for Survival Outcomes
Author(s): Na Bo* and Yue Wei and Lang Zeng and Ying Ding and CHAERYON KANG
Companies: University of Pittsburgh and University of Pittsburgh and University of Pittsburgh and University of Pittsburgh and Dept. of Biostatistics, University of Pittsburgh
Keywords: age-related macular degeneration; counterfactual outcome; heterogeneous treatment effect; precision medicine; treatment rule recommendation
Abstract:

One important aspect of precision medicine is to allow physicians to choose the most suitable treatment for their patients, which requires an understanding of the heterogeneity of treatment effects from a patient-centric view. With large amount of genetic data being generated, a full picture of individuals' characteristics is forming. Recent development using machine learning methods within the counterfactual framework shows great potential in analyzing such data. In this research, we develop a meta-learner approach to estimate individual treatment effect (ITE) for survival outcome. We consider two algorithms, T-learner and X-learner, each combined with three machine learning methods: random survival forest, Bayesian accelerate failure time model, and deep survival neural network. The performance of these methods is compared through simulations. We then apply the methods on a randomized clinical trial (RCT), the AREDS study for age-related macular degeneration, to estimate ITEs and identify genetic variants that contribute to the heterogeneous treatment effects. The resulting treatment recommendation rules are applied to a subsequent RCT, AREDS2, as an external validation.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2022 program